


I-287

Cat. No.:	HY-148016
CAS No.:	2014368-93-3
Molecular Formula:	C ₃₀ H ₃₀ ClFN ₄ O ₄
Molecular Weight:	565.04
Target:	Protease Activated Receptor (PAR); ERK
Pathway:	GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	I-287 is a orally active selective PAR2 inhibitor that acting as a negative allosteric regulator on G α_q and G $\alpha_{12/13}$ activity and their downstream effectors. I-287 reduces Complete Freund's adjuvant (HY-153808)-induced inflammation in mice and can be used for inflammation/immunology research ^[1] .									
IC₅₀ & Target	ERK1	ERK2								
In Vitro	<p>I-287 (0-60 μM; 15-30 min) inhibits PAR2-mediated activation of Gα_q and G$\alpha_{12/13}$ but not Gi/o proteins while has no effect on PAR2-mediated recruitment of βarrestin2 and receptor internalization^[1].</p> <p>I-287 (0-60 μM; 15-30 min) inhibits PAR2-mediated ERK1/2 activation in HEK293 cells^[1].</p> <p>I-287 (10 μM; 30 min) inhibits PAR2-induced secretion of IL-8 cytokine in HCT-116 and A549 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HEK-293 cells</td> </tr> <tr> <td>Concentration:</td> <td>0-60 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>15 min</td> </tr> <tr> <td>Result:</td> <td>Inhibited PAR2-mediated ERK1/2 activation in HEK293 cells.</td> </tr> </table>		Cell Line:	HEK-293 cells	Concentration:	0-60 μ M	Incubation Time:	15 min	Result:	Inhibited PAR2-mediated ERK1/2 activation in HEK293 cells.
Cell Line:	HEK-293 cells									
Concentration:	0-60 μ M									
Incubation Time:	15 min									
Result:	Inhibited PAR2-mediated ERK1/2 activation in HEK293 cells.									
In Vivo	<p>I-287 (50 mg/kg for p.o.) reduces Complete Freund's adjuvant (HY-153808)-induced inflammation in C57BL/6J mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CFA-induced paw inflammation in adult male C57BL/6J mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage (p.o.) following the CFA</td> </tr> <tr> <td>Result:</td> <td>Reduces CFA-induced inflammation in C57BL/6J mice</td> </tr> </table>		Animal Model:	CFA-induced paw inflammation in adult male C57BL/6J mice ^[1]	Dosage:	50 mg/kg	Administration:	Oral gavage (p.o.) following the CFA	Result:	Reduces CFA-induced inflammation in C57BL/6J mice
Animal Model:	CFA-induced paw inflammation in adult male C57BL/6J mice ^[1]									
Dosage:	50 mg/kg									
Administration:	Oral gavage (p.o.) following the CFA									
Result:	Reduces CFA-induced inflammation in C57BL/6J mice									

REFERENCES

[1]. Avet C, et.al. The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects. Commun Biol. 2020 Nov 27;3(1):719.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA